Lepu Biotechnology
The profile is currenly unclaimed by the seller. All information is provided by CB Insights.
Founded Year
2018Stage
IPO | IPOTotal Raised
$317.23MDate of IPO
2/23/2022Expert Collections containing Lepu Biotechnology
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Lepu Biotechnology is included in 3 Expert Collections, including Cancer.
Cancer
3,605 items
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Biopharma Tech
838 items
Latest Lepu Biotechnology News
Jul 3, 2019
July 3 Financial Quick Takes: Mega-round for China’s Lepu; plus Citryll, Jibeier and Calliditas 2:42 PM Share Shiyu Capital leads Lepu’s $131M A round Lepu Biotechnology Co. Ltd. closed a RMB900 million ($130.7 million) series A round led by Shiyu Capital. Sumin Investment, Kaiyuan Guochuang, Suzhou Xinrui, Le Cheng Medical, and existing investor Lepu Medical Technology (Beijing) Co. Ltd. (SZSE:300003) participated in the financing. Founded last year, Lepu has PD-1 and PD-L1 inhibitors, an oncolytic virus and multiple antibody-drug conjugates (ADCs) in Phase I-III testing. Citryll raises €15M series A from Chinese and Dutch investors Citryll B.V. (Oss, the Netherlands) raised €15 million ($16.9 million) in a series A round from ModiQuest B.V. (Oss, the Netherlands), BOM Brabant Ventures, the BrightGene International (Hong Kong) Ltd. unit of BrightGene Bio-medical technology Co. Ltd. (Suzhou, China) and Curie Capital. The company is developing antibodies that block the formation of neutrophil extracellular traps by binding to N-terminal citrullinated epitopes in histones, which could treat autoimmune diseases such as lupus and rheumatoid arthritis. Jibeier looks to list in Shanghai The Shanghai Stock Exchange accepted an application from Jiangsu Jibeier Pharmaceutical Co. Ltd. (Zhenjiang, China) to list on its new science and technology innovation board. The company proposed to raise up to RMB690 million ($100.2 million). The pharma develops chemical preparations and traditional Chinese medicines. Calliditas raises $22.6M A year after going public on NASDAQ Stockholm, renal disease company Calliditas Therapeutics AB (SSE:CALTX) raised SEK210.3 million ($22.6 million) through the sale of 3.5 million shares at SEK60 in a private placement. Investors included BVF Partners L.P. (see "Calliditas Raises Over $70M in Swedish IPO" ). User Sign in
Lepu Biotechnology Web Traffic
Lepu Biotechnology Rank
When was Lepu Biotechnology founded?
Lepu Biotechnology was founded in 2018.
Where is Lepu Biotechnology's headquarters?
Lepu Biotechnology's headquarters is located at 2nd Floor, Building 41, No. 518, Xinzhuan Road, Songjiang District, Songjiang District.
What is Lepu Biotechnology's latest funding round?
Lepu Biotechnology's latest funding round is IPO.
How much did Lepu Biotechnology raise?
Lepu Biotechnology raised a total of $317.23M.
Who are the investors of Lepu Biotechnology?
Investors of Lepu Biotechnology include Vivo Capital, Shanghai Biomedical Industry Equity Investment Fund Management, Haitong Leading Capital Management, Sunshine Insurance Group, Ping An Capital and 11 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.